News Archive

2020 Grad Profile: Cancer Center Research Inspires A Passion

READ MORE

New Safeguards and Procedures Allow Cancer Care, Research to Continue During COVID-19 Pandemic

READ MORE

UArizona Launches Two-Way Texting System to Gather and Provide Critical COVID-19 Health Data

READ MORE

UArizona Cancer Center Joins Cancer Prevention and Control Research Network

READ MORE

UArizona Cancer Center Appoints Dr. Babiker to Leadership Position

READ MORE

UArizona Cancer Center Receives $6.9M Grant for Skin Cancer Prevention Study

READ MORE

UArizona Hockey Team to Host Sixth Annual ‘Pink the Rink’ on Jan. 18

READ MORE

Many Non-Hodgkin’s Lymphoma Patients Can Skip Radiation, Suggests Study Led by UArizona Researcher

Results from a SWOG Cancer Research Network study, led by Daniel Persky, MD, found many patients with the most common type of non-Hodgkin’s lymphoma can skip radiation treatment, reducing both costs and the time to heal from treatment.

READ MORE

UArizona Cancer Center Receives $6.85M Grant to Continue Native American Cancer Research, Training, Outreach Program

Since 2002, the UArizona Cancer Center has partnered with Northern Arizona University through the Partnership for Native American Cancer Prevention (NACP) to alleviate the unequal burden of cancer among Native Americans. NACP is one of 16 National Cancer Institute (NCI) Partnerships to Advance Cancer Health Equity (PACHE), but the NACP partnership between the UArizona Cancer Center and NAU is the only one dedicated solely to the Native American population.

READ MORE

UA Cancer Center Receives $8.6M Grant to Lead One of Three NCI Clinical Trials Networks

Under this funding mechanism, the UA Cancer Center serves as a lead academic organization with 12 affiliated organizations working together to perform early-phase cancer-prevention clinical trials. The network is composed of a team of physicians from diverse specialties, statisticians, clinical staff, data managers, pathologists, translational scientists and other personnel with extensive experience in early-phase (phase 0, I or II) cancer-prevention clinical trials.

READ MORE